0001628280-21-009298.txt : 20210506 0001628280-21-009298.hdr.sgml : 20210506 20210506160827 ACCESSION NUMBER: 0001628280-21-009298 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20210506 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210506 DATE AS OF CHANGE: 20210506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aurinia Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001600620 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36421 FILM NUMBER: 21897776 BUSINESS ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 BUSINESS PHONE: 250-708-4272 MAIL ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 8-K 1 auph-20210506.htm 8-K auph-20210506

Washington, D.C. 20549

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 6, 2021
Aurinia Pharmaceuticals Inc.
(Exact name of registrant as specified in its charter)
Canada 001-36421 46-4129078
(State or Other Jurisdiction of Incorporation)
(Commission File No.)
(IRS Employer Identification No.)

#1203-4464 Markham Street
Victoria, British Columbia
V8Z 7X8
(250) 708-4272
(Address and telephone number of registrant's principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class 
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Shares, without par value AUPH The Nasdaq Stock Market LLC
Common Shares, without par valueAUPToronto Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Item 2.02Results of Operations and Financial Condition.

On May 6, 2021, Aurinia Pharmaceuticals Inc. ("Aurinia") issued a press release announcing its financial results for the quarter ended March 31, 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information in this Current Report on Form 8-K and the exhibit hereto are being furnished pursuant to this Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K and the exhibit hereto, that is furnished pursuant to this Item 2.02 shall not be incorporated by reference in any of Aurinia's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.

Item 9.01Financial Statements and Exhibits
(d) Exhibits.
Exhibit No.Description
104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 6, 2021

By:/s/ Joseph Miller
Name:Joseph Miller
Chief Financial Officer

EX-99.1 2 exhibit991_q12021pressrele.htm EX-99.1 Document

Exhibit 99.1

- Quarter highlights include FDA approval, launch and early market penetration of LUPKYNISTM as the first approved oral therapy for lupus nephritis (LN) –
-Over 250 patient start forms received by the end of the first quarter -
- Cash and cash equivalents, and investments of $360.9 million at March 31, 2021
- Conference call to be hosted today at 5:00 p.m. ET -
VICTORIA, British Columbia – May 6, 2021 - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the first quarter ended March 31, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars.
“2021 started with the FDA approval of LUPKYNIS, the first FDA-approved oral treatment for active lupus nephritis – a devastating complication of lupus,” commented Peter Greenleaf, President and Chief Executive Officer of Aurinia. “Our pivotal decision and work to build a world-class commercial infrastructure prior to approval ultimately led to Aurinia being able to make LUPKYNIS immediately available to patients and physicians following approval. Since that time, the Aurinia team has been encouraged by the feedback we are receiving from physicians and patients and our confidence has only grown as we continue to understand the tremendous need and value of LUPKYNIS, and work to accelerate broader adoption across the underserved LN population.”
Recent Highlights
FDA Approval and Commercial Launch of LUPKYNIS
On January 22, 2021, the FDA approved LUPKYNIS in combination with a background immunosuppressive therapy regimen to treat adult patients with active LN.
Commercial Activities
Engaged with over 6,000 rheumatologists and nephrologists;
Received over 250 patient start forms during the first quarter (covering 48 business days post-FDA approval);
Converted nearly 40% of patient start forms to patients on therapy by the end of the first quarter; and
Launched LUPKYNIS Patient Marketing Campaign, Focus on the Fight, in April 2021.
“Since launch, the commercial team has focused on educating their customers on the urgency needed in reducing proteinuria for patients with active LN. With more than 250 patient start forms and 40% of those patients on therapy after the first two months on the market, more than 6,000 clinical interactions, continued gradual expansion of payor coverage, and our Aurinia Alliance patient support program fully operational, the LUPKYNIS trajectory is on track against our internal projections. Furthermore, we anticipate that our market access will continue to improve as the rate of COVID vaccinations in the United States continues to climb and healthcare centers re-open their doors to patients,” commented Max Colao, Chief Commercial Officer at Aurinia.


Upcoming Milestones
Anticipate filing a marketing authorization application (MAA) with the European Medicines Agency (EMA) during the first half of 2021 with partner, Otsuka;
Abstracts discussing voclosporin accepted for presentation at the Annual European Congress of Rheumatology (EULAR 2021 Congress), June 2 – 5, 2021, and at the Nephrology Virtual Congress (ERA-EDTA 2021), June 5 – 8, 2021;
Expect to initiate a study of voclosporin in adolescent patients (VOCAL study) during the second half of 2021; and
Anticipate reporting top-line results from the ongoing AURORA-2 continuation study during the first quarter of 2022.

Financial Liquidity at March 31, 2021

As of March 31, 2021, Aurinia had cash and cash equivalents and investments of $360.9 million compared to $422.7 million at December 31, 2020. The decrease is primarily related to the commercial infrastructure spend to support the launch of LUPKYNIS in addition to an upfront payment made as part of a collaborative agreement with Lonza to build a dedicated manufacturing facility (also referred to as “monoplant”) and one-time payment to a related party upon achievement of specific milestones.

Net cash used in operating activities was $53.5 million for the quarter ended March 31, 2021 compared to $22.6 million for the quarter ended March 31, 2020. The increase is primarily due to the commercial infrastructure spend to support the launch of LUPKYNIS in addition to a one-time payment to a related party upon achievement of specific milestones. In the prior year, the Company was still in the development phase of LUPKYNIS and as a result, did not incur any material related selling expenses.
The Company believes that it has sufficient financial resources to fund its current plans, which include funding commercial activities, including our FDA related post approval commitments, manufacturing and packaging of commercial drug supply, conducting our planned research and development (R&D) programs, and operating activities into at least 2023.
Financial Results for the Quarter Ended March 31, 2021
For the quarter ended March 31, 2021, Aurinia recorded a net loss of $50.4 million or $0.40 net loss per common share, as compared to a net loss of $25.9 million or $0.23 net loss per common share for the quarter ended March 31, 2020.
Revenues were $0.9 million and $30 thousand for the quarters ended March 31, 2021 and March 31, 2020, respectively. The increase was the result of the commercial sales of LUPKYNIS, which began in January 2021.
Cost of sales were $48 thousand and nil for the quarters ended March 31, 2021 and March 31, 2020, respectively. The increase was the result of commercial sales of LUPKYNIS and drug substance. Gross margin for the quarter ended March 31, 2021 was approximately 95%.
Selling, general and administrative (SG&A) expenses were $39.3 million and $11.1 million for the quarters ended March 31, 2021 and March 31, 2020, respectively. The increase was primarily due to the expansion of the commercial infrastructure, administrative functions and patient assistance programs to support the launch of LUPKYNIS. SG&A share-based compensation expense for the quarter ended March 31, 2021 was $6.6 million.
R&D expenses were $9.8 million and $13.8 million for the quarters ended March 31, 2021 and March 31, 2020, respectively. The decrease was primarily due to lower Contract Research Organization (CRO) expenses and other third-party clinical trial expenses following the approval of LUPKYNIS, including a reduction in NDA preparation costs, capitalization of supply costs following approval, and termination of the dry eye trial during the fourth quarter of 2020. R&D share-based compensation expense for the quarter ended March 31, 2021 was $1.1 million.
This press release is intended to be read in conjunction with the Company’s unaudited condensed consolidated financial statements and Management's Discussion and Analysis for the quarter ended March 31, 2021 in the Company’s Quarterly

Report on Form 10-Q, which is accessible on Aurinia's website at www.auriniapharma.com, on SEDAR at www.sedar.com or on EDGAR at www.sec.gov/edgar.
Conference Call Details
Aurinia will host a conference call and webcast to discuss the quarter ended March 31, 2021 financial results today, Thursday, May 6, 2021 at 5:00 p.m. ET. The audio webcast can be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. In order to participate in the conference call, please dial +1-888-506-0062 (toll-free U.S.) or +1-973-528-0011 (international); entry code: 662377. A replay of the conference call will also be available on Aurinia’s website approximately two hours after the live call is completed.
About Lupus Nephritis
LN is a serious progression of systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease. About 200,000-300,000 people live with SLE in the U.S. and approximately one out of three of these individuals have already developed LN at the time of SLE diagnosis. If poorly controlled, LN can lead to permanent and irreversible tissue damage within the kidney, resulting in kidney failure. Black and Asian individuals with SLE are four times more likely to develop LN and individuals with Hispanic ancestry are approximately twice as likely to develop the disease when compared with Caucasian individuals. Black and Hispanic individuals with SLE also tend to develop LN earlier and have poorer outcomes when compared to Caucasian individuals.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active LN. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
Forward-Looking Statements
Certain statements made in this press release may constitute forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable United States securities law. These forward-looking statements or information include but are not limited to statements or information with respect to: Aurinia’s estimates as to the number of patients with SLE in the U.S. and the proportion of those persons who will develop LN; Aurinia’s belief that it is on track to meet its internal expectations for the prescribing of LUPKYNIS; Aurinia’s belief that it has sufficient financial resources to fund its current plans until 2023; Aurinia’s belief that it has a world-class commercial infrastructure; Aurinia’s belief that commercial activity will accelerate as the rate of COVID vaccinations in the United States continue to climb and healthcare centers re-open their doors to patients; the planned timing to file an MAA with the EMA; the planned presentation of abstracts covering voclosporin; the timing to initiate the VOCAL study; and the planned timing for reporting top-line results from the ongoing AURORA-2 continuation study. It is possible that such results or conclusions may change based on further analyses of these data. Words such as “anticipate”, “will”, “believe”, “estimate”, “expect”, “intend”, “target”, “plan”, “goals”, “objectives”, “may” and other similar words and expressions, identify forward-looking statements. We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions about: the accuracy of reported data from third party studies and reports; that Aurinia’s intellectual property rights are valid and do not infringe the intellectual property rights of third parties; Aurinia’s assumptions relating to the capital required to fund operations into 2023; the assumption that Aurinia’s current good relationships with its suppliers, service providers and other third parties will be maintained; assumptions relating to the burn rate of Aurinia’s cash for operations; the relationship between COVID vaccinations and patient treatment; and that Aurinia’s third party service providers will comply with their contractual obligations. Even though the management of Aurinia believes that the assumptions made, and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate.

Forward-looking information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of Aurinia to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements or information. Such risks, uncertainties and other factors include, among others, the following: difficulties Aurinia may experience in completing the commercialization of voclosporin; the market for the LN business may not be as estimated; Aurinia may have to pay unanticipated expenses; Aurinia may not be able to obtain sufficient supply to meet commercial demand for voclosporin in a timely fashion; unknown impact and difficulties imposed by the COVID-19 pandemic on Aurinia’s business operations including nonclinical, clinical, regulatory and commercial activities; the results from Aurinia’s clinical studies and from third party studies and reports may not be accurate; Aurinia’s third party service providers may not, or may not be able to, comply with their obligations under their agreements with Aurinia; and Aurinia’s assets or business activities may be subject to disputes that may result in litigation or other legal claims. Although Aurinia has attempted to identify factors that would cause actual actions, events, or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actual results, performances, achievements, or events to not be as anticipated, estimated or intended. Also, many of the factors are beyond Aurinia’s control. There can be no assurance that forward-looking statements or information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, you should not place undue reliance on forward-looking statements or information.
All forward-looking information contained in this presentation is qualified by this cautionary statement. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedar.com or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar, or on Aurinia’s website at www.auriniapharma.com.

Investor Contact:
Glenn Schulman, PharmD, MPH
Corporate Communications, Aurinia
or ir@auriniapharma.com

Corporate Contact:
Dana Lynch
Corporate Communications, Aurinia

Media Contact:
Stefan Riley
Ten Bridge Communications


(in thousands)

March 31, 2021December 31, 2020
Current assets
Cash and cash equivalents$156,591 $272,350 
Short-term investments191,668 125,979 
Accounts receivable, net1,187 — 
Inventories, net15,936 13,927 
Prepaid expenses and other current assets6,864 7,171 
Total current assets372,246 419,427 
Non-current assets
Long-term investments12,603 24,380 
Other non-current assets11,856 247 
Property and equipment, net4,758 4,786 
Acquired intellectual property and other intangible assets, net9,854 9,332 
Right-of-use assets5,761 5,489 
Total assets417,078 463,661 
Current liabilities
Accounts payable and accrued liabilities17,694 24,797 
Other current liabilities (of which $2,000 and $6,000, due to related party in 2021 and 2020, respectively)2,382 6,412 
Operating lease liabilities1,075 788 
Total current liabilities21,151 31,997 
Non-current liabilities
Other non-current liabilities17,893 16,295 
Operating lease liabilities7,806 7,619 
Total liabilities46,850 55,911 
Common shares - no par value, unlimited shares authorized, 128,121 and 126,725 shares issued and outstanding as at March 31, 2021 and December 31, 2020, respectively952,673 944,328 
Additional paid-in capital43,889 39,383 
Accumulated other comprehensive loss(799)(805)
Accumulated deficit(625,535)(575,156)
Total shareholder’s equity370,228 407,750 
Total liabilities and shareholders’ equity$417,078 $463,661 


(in thousands, except per share data)
Three months ended
March 31,
Product revenue, net$884 $— 
License revenue30 30 
Total revenue914 30 
Operating expenses:
Cost of sales48 — 
Selling, general and administrative39,282 11,053 
Research and development9,833 13,835 
Amortization of intangible assets523 286 
Other expense, net1,771 1,916 
Total cost and operating expenses51,457 27,090 
Loss from operations(50,543)(27,060)
Interest income172 890 
Net loss before income taxes(50,371)(26,170)
Income tax expense (benefit)8 (238)
Net loss$(50,379)$(25,932)
Basic and diluted loss per share$(0.40)$(0.23)
Weighted-average common shares outstanding used in computation of basic and diluted loss per share127,401 112,209 
EX-101.SCH 3 auph-20210506.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 auph-20210506_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 auph-20210506_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 auph-20210506_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Type Document Type Entity Address, Postal Zip Code Entity Address, Postal Zip Code Local Phone Number Local Phone Number Amendment Flag Amendment Flag Written Communications Written Communications City Area Code City Area Code Title of 12(b) Security Title of 12(b) Security Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Soliciting Material Soliciting Material Document Period End Date Document Period End Date Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Cover [Abstract] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol EX-101.PRE 7 auph-20210506_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 aurinalogo1.jpg begin 644 aurinalogo1.jpg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end XML 9 auph-20210506_htm.xml IDEA: XBRL DOCUMENT 0001600620 2021-05-06 2021-05-06 0001600620 2021-01-25 2021-01-25 0001600620 false 8-K 2021-05-06 Aurinia Pharmaceuticals Inc. Z4 001-36421 46-4129078 #1203-4464 Markham Street Victoria BC V8Z 7X8 250 708-4272 false false false false Common Shares, without par value AUPH NASDAQ false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover Page
May 06, 2021
Jan. 25, 2021
Cover [Abstract]    
Document Type 8-K  
Document Period End Date May 06, 2021  
Entity Registrant Name Aurinia Pharmaceuticals Inc.  
Entity Incorporation, State or Country Code   Z4
Entity File Number   001-36421
Entity Tax Identification Number   46-4129078
Entity Address, Address Line One #1203-4464 Markham Street  
Entity Address, City or Town Victoria  
Entity Address, State or Province BC  
Entity Address, Postal Zip Code V8Z 7X8  
City Area Code 250  
Local Phone Number 708-4272  
Written Communications   false
Soliciting Material   false
Pre-commencement Tender Offer   false
Pre-commencement Issuer Tender Offer   false
Title of 12(b) Security   Common Shares, without par value
Trading Symbol   AUPH
Security Exchange Name   NASDAQ
Entity Emerging Growth Company false  
Entity Central Index Key 0001600620  
Amendment Flag false  
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 2 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.auriniapharma.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports auph-20210506.htm auph-20210506.xsd auph-20210506_cal.xml auph-20210506_def.xml auph-20210506_lab.xml auph-20210506_pre.xml exhibit991_q12021pressrele.htm http://xbrl.sec.gov/dei/2020-01-31 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "auph-20210506.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 2, "dts": { "calculationLink": { "local": [ "auph-20210506_cal.xml" ] }, "definitionLink": { "local": [ "auph-20210506_def.xml" ] }, "inline": { "local": [ "auph-20210506.htm" ] }, "labelLink": { "local": [ "auph-20210506_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "auph-20210506_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "auph-20210506.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "auph", "nsuri": "http://www.auriniapharma.com/20210506", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210506.htm", "contextRef": "i241c5a549c2e41638afeac48bc65f850_D20210506-20210506", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.auriniapharma.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210506.htm", "contextRef": "i241c5a549c2e41638afeac48bc65f850_D20210506-20210506", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001628280-21-009298-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-21-009298-xbrl.zip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